Akriderm SK ointment d / nar. approx. 0,05% + 3% tube 15g

Release form, composition and packaging

Ointment for external use 0.05% + 3% translucent, from white to white with a yellowish tinge

the presence of a weak specific smell is allowed.

100 g

betamethasone dipropionate in terms of 100% substance 0.064 g,

- which is equivalent to betamethasone 0.05 g

salicylic acid in terms of 100% substance 3 g

liquid paraffin (liquid paraffin) - 10 g, petroleum jelly - up to 100 g.

15 g - aluminum tubes (1) - cardboard packs.

30 g - aluminum tubes (1) - cardboard packs.

pharmachologic effect

Combination of corticosteroids with an antiseptic agent with keratolytic action.

Indications for use

Ointment AkridermSK is used for the treatment of subacute and chronic dermatoses, sensitive to external corticosteroid therapy, accompanied by hyperkeratosis:

- psoriasis

- atopic dermatitis (neurodermatitis)

- lichen planus

- eczema

- dyshydratic dermatitis

- ichthyosis and ichthyosiform changes.

Contraindications for use

- hypersensitivity to any component of the drug

- tuberculosis of the skin

- viral skin infections

- vaccination

- perioral dermatitis

- rosacea (rosacea).

Dosage regimen

The drug AkridermSK is applied with a thin layer on the inflamed surface 2 times / day, lightly rubbing.

In milder cases, a single use is sufficient.

The duration of treatment is usually limited to 3 weeks.

If a long course of therapy is required, it is recommended to use the drug less often, for example, every other day.

In the treatment of chronic diseases under the constant supervision of a physician, treatment should be continued for some time after the disappearance of all symptoms in order to avoid recurrence of the disease.

The use of the drug in children under 12 years of age is carried out under the supervision of the attending physician.

Overdose

If AkridermSK ointment is applied to large surfaces of inflamed, and therefore more permeable skin, for a long period (more than 3 weeks), using an occlusive dressing, as well as with prolonged use in children, enhanced absorption of active components and the manifestation of systemic effects of betamethasone are not excluded and salicylic acid.

In case of overdose, the use of the drug should be discontinued and consult a doctor.

Side effect

Side effects can be both local (at the site of application) and systemic (a consequence of systemic absorption of active ingredients).

At the site of application, a burning sensation, itching, folliculitis, acne, striae, skin atrophy, depigmentation and hypertrichosis may develop.

Very rarely, with prolonged use on large surfaces of the skin, when using occlusive dressings, increased percutaneous absorption of the active components of the drug is possible, which can cause systemic side effects manifested in the form of symptoms of GCS overdose (growth retardation, reversible suppression of the ACTH system, Cushing's syndrome, benign increase intracranial pressure after the end of treatment, hyperglycemia, glycosuria, hypokalemia, increased blood pressure)

side effects caused by salicylates: pallor, fatigue, drowsiness, hyperventilation and tachypnea, nausea, vomiting, hearing impairment, confusion, etc.

In case of side effects, you should consult a doctor.

In the event of a secondary skin infection, adequate antifungal and antibiotic therapy should be used.

Do not use antifungal and antibacterial drugs yourself!

Consult your doctor!

Drug interactions

There were no clinically significant interactions with other drugs.

Application during pregnancy and lactation

The use of AkridermSK ointment in pregnant women tolerance

Name ENG

AKRIDERM SK

Clinical and pharmacological group

Drug with anti-inflammatory and keratolytic action for external use

ATX code

Betamethasone in combination with other drugs

Dosage

0.05% + 3% x 15g

Structure

1 g of ointment contains: active substances: betamethasone dipropionate 0.64 mg and salicylic acid 30 mg

auxiliary substances: petroleum jelly, liquid paraffin.

Indications

Local treatment of dermatoses, accompanied by hyperkeratosis: psoriasis, limited and diffuse neurodermatitis, lichen planus, eczema, dyshidrotic dermatitis, ichthyosis and ichthyosiform changes.

Storage conditions and periods

At a temperature of 15-25 degrees.

Expiration date: 3 years

INN / Active ingredient

salicylic acid, betamethasone

Contraindications

Hypersensitivity to any of the components of the drug, skin tuberculosis, skin manifestations of syphilis, chickenpox, herpes simplex, post-vaccination skin reactions, open wounds, lactation and children under 1 year of age

additionally for Akriderm: trophic ulcers of the leg, rosacea, acne vulgaris

additionally for the drug Akriderm GK: in the treatment of external otitis media perforation of the tympanic membrane

additionally for Akriderm SK: perioral dermatitis.

Specifications

Category

Psoriasis

Scope of the drug

Dermatology

Release form

Ointment

Manufacturer country

Russia

Package quantity, pcs

one

Minimum age from

1 year

Way of introduction

On the skin

Vacation conditions

Without recipe

Brand name

Akrikhin

The amount of the dosage form in the primary package

15 g

Primary packaging type

Tuba

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

D07XC01 Betamethasone, in combination with other drugs

Dosage form

Ointment for external use

The target audience

Children

Expiration date in days

1095

Package weight, g

15

Mode of application

:

Outwardly.

Akriderm SK is applied with a thin layer on the affected skin area 2 times a day - in the morning and in the evening.

A different frequency of use can be established by a doctor, based on the severity of the disease.

In mild cases, it is sufficient to apply the ointment, as a rule, once a day

more severe lesions may require more frequent use.

Pharmaco-therapeutic group

:

Topical glucocorticosteroid + keratolytic agent

Dosage (volume) of the substance in the preparation

:

betamethasone dipropionate 0.064 g, which is equivalent to betamethasone 0.05 g, salicylic acid 3 g

Information on technical characteristics, delivery set, country of manufacture